Doripenem

From WikEM
Jump to: navigation, search

General

  • Type: Carbapenem (broad-spectrum beta-lactamase)
  • Dosage Forms: IV
  • Common Trade Names: Doribax

Adult Dosing

Intra-abdominal infection, complicated

  • 500mg IV q8h x5-14 days

UTI, complicated

  • 500mg IV q8h x10 days

Anthrax, systemic

  • 500mg IV q8h for at least 2 wk as part of multi-drug regimen

Pediatric Dosing

Anthrax, systemic

  • Neonates >32 weeks gestation
    • 20-30 mg/kg/day IV divided q8-12h for two weeks as part of multi-drug regimen
  • 1+ month old
    • 120 mg/kg/day IV divided q8h for at least two weeks as part of multi-drug regimen
      • Max: 1 g/dose

Special Populations

  • Pregnancy Rating: B
  • Lactation: May use while breastfeeding
  • Renal Dosing
    • Adult
      • CrCl 30-50: 250mg IV q8h
      • CrCl 10-30: 250mg IV q12h
      • CrCl <10: Not defined
      • HD: Not defined
    • Pediatric
      • May be required, but specifics not defined
  • Hepatic Dosing
    • Adult
      • No adjustment
    • Pediatric
      • May be required, but specifics not defined

Contraindications

  • Allergy to class/drug
  • Anaphylactic reaction to beta-lactams
  • Inhalational use
  • Ventilator-associated pneumonia
  • Caution:
    • Hypersensitivity to beta-lactams
    • Hypersensitivity to multiple allergens
    • Renal impairment
    • CNS disorder
    • Seizure history or risk
    • Recent abx-associated colitis

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 1h
  • Metabolism: Kidney minimally
  • Excretion: Urine 85% (70% unchanged), feces <1%
  • Mechanism of Action: Inhibits cell wall synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp S
Enterococcus faecalis I
Enterococcus faecium R
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis S
C. jeikeium X1
L. monocytogenes S
Gram Negatives N. gonorrhoeae X2
N. meningitidis S
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ S
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos S
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii S
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. I
Pseudomonas aeruginosa S
Burkholderia cepacia I
Stenotrophomonas maltophilia R
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp R
Mycoplasm pneumoniae R
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis S
Prevotella melaninogenica S
Clostridium difficile X2
Clostridium (not difficile) S
Fusobacterium necrophorum S
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2014